Boothbay Fund Management, LLC Verastem, Inc. Transaction History

Boothbay Fund Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.02 - $1.83 $40,363 - $72,416	-39,572 Reduced 43.53%	51,331 $60,000
Q1 2022 May 16, 2022	BUY	$1.06 - $2.1 $18,315 - $36,285	17,279 Added 23.47%	90,903 $128,000
Q4 2021 Feb 14, 2022	SELL	$2.05 - $3.2 $266,588 - $416,137	-130,043 Reduced 63.85%	73,624 $151,000
Q3 2021 Nov 15, 2021	SELL	$2.54 - $4.07 $6,052 - $9,698	-2,383 Reduced 1.16%	203,667 $627,000
Q2 2021 Aug 16, 2021	SELL	$2.57 - $4.85 $400,375 - $755,571	-155,788 Reduced 43.05%	206,050 $839,000
Q1 2021 May 17, 2021	BUY	$1.9 - $2.82 $128,248 - $190,347	67,499 Added 22.93%	361,838 $894,000
Q4 2020 Feb 12, 2021	BUY	$1.15 - $2.4 $115,512 - $241,070	100,446 Added 51.8%	294,339 $627,000
Q3 2020 Nov 16, 2020	SELL	$1.11 - $1.68 $15,017 - $22,728	-13,529 Reduced 6.52%	193,893 $235,000
Q2 2020 Aug 14, 2020	SELL	$1.69 - $4.2 $615,900 - $1.53 Million	-364,438 Reduced 63.73%	207,422 $357,000
Q1 2020 May 15, 2020	BUY	$1.26 - $3.38 $720,543 - $1.93 Million	571,860 New	571,860 $1.51 Million
Q3 2018 Nov 14, 2018	SELL	$6.86 - $9.97 $82,320 - $119,640	-12,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$2.88 - $8.67 $34,560 - $104,040	12,000 New	12,000 $83,000

297K

Ticker VSTM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 210,000,000
Market Cap $1.29B
Description
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.